Business · 10/03/1994Updated: 10/15/2026 · 1 min read
Prospective Grant of Exclusive and Co-Exclusive Licenses: In-Vivo Imaging and Radiotherapy Targeting Antigens Recognized by the B1, B3 and B5 Antibodies
Summary
The National Institutes of Health (NIH) is contemplating the grant of exclusive and co-exclusive licenses to NeoRx Corporation and ImmunoMedics, Inc. for a patent related to antibodies targeting antigens recognized by the B1, B3 and B5 antibodies.
Original source language: Federal Register — Health and Human ServicesOpen original release →